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Background: In sporadic Tauopathies, neurofibrillary degeneration (NFD) is characterised by the intraneuronal
aggregation of wild-type Tau proteins. In the human brain, the hierarchical pathways of this neurodegeneration
have been well established in Alzheimer’s disease (AD) and other sporadic tauopathies such as argyrophilic grain
disorder and progressive supranuclear palsy but the molecular and cellular mechanisms supporting this progression
are yet not known. These pathways appear to be associated with the intercellular transmission of pathology, as
recently suggested in Tau transgenic mice. However, these conclusions remain ill-defined due to a lack of toxicity
data and difficulties associated with the use of mutant Tau.
Results: Using a lentiviral-mediated rat model of hippocampal NFD, we demonstrated that wild-type human Tau
protein is axonally transferred from ventral hippocampus neurons to connected secondary neurons even at distant
brain areas such as olfactory and limbic systems indicating a trans-synaptic protein transfer. Using different
immunological tools to follow phospho-Tau species, it was clear that Tau pathology generated using mutated Tau
remains near the IS whereas it spreads much further using the wild-type one.
Conclusion: Taken together, these results support a novel mechanism for Tau protein transfer compared to
previous reports based on transgenic models with mutant cDNA. It also demonstrates that mutant Tau proteins are
not suitable for the development of experimental models helpful to validate therapeutic intervention interfering
with Tau spreading.
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AD is the most common neurodegenerative disorder. It
results from an accumulation of extracellular amyloid de-
posits and a neurodegenerative process called NFD, which
is characterised by the intraneuronal aggregation of the
microtubule-associated Tau proteins. This Tau pathology
has been associated with a number of neurodegenerative
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unless otherwise stated.where mutations have not been identified on the Tau gene
(MAPT), patients presenting fronto-temporal dementia
with parkinsonism, associated with chromosome 17
(FTDP-17), exhibit Tau mutations [1]. These mutations
have been used to develop animal models with Tau aggre-
gation and NFD to decipher the role of Tau in tauopathies
[2,3]. However, the relevance of this approach remains un-
known, as mutant Tau proteins show a higher nucleation
process than WT Tau and fibrillogenesis, often leading to
rapid neuronal death [4,5]. Moreover, in FTDP-17, there is
no specific neural network affected by the Tau pathology.
Conversely, certain sporadic tauopathies display hierarch-
ical pathways of NFD. For example, in AD, neurodegener-
ation begins in the trans-entorhinal cortex, spreads to thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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polymodal and unimodal association areas and eventually
invades the entire cerebral cortex [6-8]. In progressive
supranuclear palsy, another tauopathy, a specific pathway
of NFD has also been identified leading from subcortical
structures to the primary motor cortex through the ped-
unculopontine nucleus and eventually to other frontal re-
gions [9]. The pathways of NFD have also been described
for other tauopathies, such as argyrophilic grain disease, in
which Tau aggregation starts in the vicinity of the ambient
gyrus, then spreads to the temporal lobe and subiculum
and entorhinal cortices and eventually reaches the septum,
insular cortex and cingulate gyrus [10]. In addition to dif-
ferences in these specific pathways, different Tau phos-
phorylation, isoforms, species and aggregates have also
been identified among tauopathies [1]. Taken together,
these characteristics are consistent with the presence of
different Tau strains that might transfer Tau pathology
from cell to cell [11].
Recent data suggest that Tau pathology may be induced
and propagated after the injection of Tau oligomers and/
or aggregates in either wild-type (WT) or mutated Tau
transgenic mice [11-14]. Moreover, there is evidence that
Tau aggregates can be transferred from cell to cell in vitro
[15-19]. The hierarchical pathways of NFD in tauopathies
might be associated with the trans-synaptic transfer of
Tau pathology, as recently suggested in vivo [20,21]. How-
ever, these conclusions could be hampered by at least two
factors: the use of a leaky inducible system that may in-
duces the weak expression of the transgene in the hippo-
campus, and the use of mutated Tau protein to study
propagation, as the spreading of Tau pathology is only ob-
served in sporadic tauopathies, where no mutation on
MAPT has been identified. In these models, Tau diffusion
was consistently observed in close vicinity to the expres-
sion region, and no definite evidence of a direct cell-
to-cell transfer of pathological Tau proteins was provided.
To address these two weaknesses, we took advantage of
a recently developed lentiviral-mediated rat model of hip-
pocampal NFD [22] to demonstrate that 1) WT Tau pro-
tein is transferred in a trans-synaptic manner from
primary neurons located in the CA1 region of the hippo-
campal formation to many anatomically connected sec-
ondary neurons in different brain areas including the most
distant ones (10 mm away from the injection site (IS)), 2)
Tau species found in secondary connected neurons are
mainly in a dephosphorylated form and 3) WT and mu-
tated Tau species display differential spreading of Tau
pathology.
Methods
Antibodies
Monoclonal antibody AT8 (Thermo Scientific MN1020 -
1:400 for immunolabelling) recognises phosphorylatedresidues serine 202 and threonine 205 of Tau, and mono-
clonal antibody AT100 (Thermo Scientific MN1060 -
1:400 for immunolabelling) recognises phosphorylated
residues threonine 212 and serine 214 of Tau. Tau C-ter is
a polyclonal rabbit antibody, which recognises the carb-
oxyl terminal region of Tau [23]. The monoclonal anti-
body MC1 was a generous gift from Peter Davis and
recognises conformational changes in residues seven to
nine and 313-322 (1:1000 for immunolabelling). ADx215
is a human specific anti-Tau antibody that recognizes Tau
only when Tyr18 residue is dephosphorylated [4]. Mouse
monoclonal (Invitrogen P/N-0705; 1:10000 for immunola-
belling) and rabbit polyclonal antibodies (1:10000 for
immunolabelling) to V5 recognise the V5 epitope of
tagged Tau.
Plasmid construction
The packaging construct pCMVΔR8.92 was used. The
Rev gene was inserted into the pRSV-Rev plasmid to
minimise the risk of recombination and the production
of replication-competent lentiviruses. Viral particles
were pseudotyped with the vesicular stomatitis virus G-
protein encoded in the previously described pMD2.G
plasmid [24]. cDNAs encoding the 2 + 3-10+1N4R iso-
forms of human WT Tau and mutant P301L Tau were
first cloned into the Gateway Entry pCR8/GW/TOPO
vector (Invitrogen) using TOPO TA cloning method-
ology. The Gateway LR clonase (Invitrogen) catalysed
the in vitro recombination between the Gateway Entry
pCR8/GW/TOPO vector (containing the Tau cDNA
flanked by attL sites) and the lentiviral destination vec-
tor (containing homologous attR sites). For specific
constructs, the sequence of the epitope tag V5, previ-
ously validated in vivo using immunohistochemical ana-
lysis (14 aa, GKPIPNPLLGLDST) [25], was inserted into
the cDNA encoding the 2+3-10+ isoform of the human
WT Tau between the sequences encoding exons two
and four.
Production and assay of recombinant lentiviral
vectors (LVs)
LVs vectors were amplified as previously described [24]
and encode either for V5-hTau46WT, hTau46WT, hTauP301L
or eGFP proteins. Human 293 T cells (4 × 106) were plated
onto 10-cm plates and transfected the following day with
13 μg of human Tau cDNA, 13 μg of pCMVΔR8.92, 3 μg
of pRSV-Rev and 3.75 μg of pMD.2G using the calcium
phosphate DNA precipitation procedure. Four to six hours
later, the medium was removed and replaced with fresh
medium. Forty-eight hours later, the supernatant was col-
lected and filtered. High-titre stocks were obtained through
two successive ultracentrifugation steps at 19,000 rpm
(Beckman Coulter SW 32Ti and SW 60Ti rotors) and 4°C.
The pellet was resuspended in PBS with 1% bovine serum
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Viral concentrations were determined through ELISA for
the HIV-1 p24 antigen (Gentaur BVBA). The p24 protein is
a lentiviral capsid protein that is commonly used in ELISA
assays to determine the physical titre of lentiviral
batches per ml. All viral batches were produced in ap-
propriate areas in compliance with institutional proto-
cols for genetically modified organisms according to the
‘Comité Scientifique du Haut Conseil des Biotechnolo-
gies’ (Identification Number 5258).
Neuronal cultures, microfluidic chamber system and
assays for the neuron-to-cell transfer of Tau
Briefly, glass coverslips were coated overnight at 4°C
with 0.5 mg/ml of poly-D-Lysine (SIGMA). The micro-
fluidic chamber (AXIS™, Temecula, CA) was subse-
quently placed on coated glass coverslips and sealed to
the glass. Rat Primary embryonic neuronal cultures were
performed as previously described [26], and approxi-
mately 30,000 cells each were plated in the two wells of
the somatodendritic compartment. The cultures were
maintained at 37°C for 15 days for differentiation. All
chambers had microgrooves of 450 µm in length and
10µm in width. One week post-plating, after axonal
growth across the microgrooves, a second rat primary
embryonic neuronal culture were plated in the axonal
compartment in the appropriate medium. Twenty-four
hours later, the V5-Tau-LVs or eGFP-LVs (200 ng of LVs
per well) were added to the somatodendritic compartment
after first reversing the volume gradient between the com-
partments to counteract viral diffusion. Forty-eight hours
later, eGFP fluorescence and V5 immunolabelling were ana-
lyzed. The compartments (somatodendritic and axonal)
were washed once with phosphate-buffered saline (PBS)
and fixed with 4% paraformaldehyde (PFA) for 20 min.
After removing the fixative, the cells were washed three
more times with 50 mmol/L NH4Cl and processed as de-
scribed in the immunofluorescence section.
Testing of fluidic isolation
Isolation of the different compartments in microfluidic con-
ditions without cells was also assessed using either Coo-
massie Blue or LVs particles. Coomassie Blue (2%) or LVs
particles (400 ng p24) diluted in PBS were added to the
somatodendritic compartment of microfluidic device and
PBS was added to the axonal compartment. The volume
gradient between both compartments was adapted to avoid
or to mediate diffusion across the microgrooves. 5 min, 1,
2, 24 or 48 h later, optical density at 595 nm was measured.
When LVs particles were used instead of Coomassie
Blue, the medium in both compartments was recovered
and viral RNA extracted (Nucleospin RNA Virus,
MACHEREY-Nagel, Düren, Germany). cDNAs were gen-
erated by RT-PCR and PCR done using the followingoligonucleotides specific to the viral WPRE (Woodchuck
Hepatitis Post-transcriptional Regulatory Element) (for-
ward: 5′-TAC-GCT-ATG-TGG-ATA-CGC-TGC-3′ and
reverse: 5′-AAT-TCC-CGA-TGC-GGG-GA-3′).
Animals
The animals were purchased from Janvier Laboratories
and housed in a temperature-controlled room main-
tained on a 12 h day/night cycle with food and water
provided ad libitum. The present experimental research
has been performed with the approval of an ethics com-
mittee (‘Comité d’éthique en expérimentation animale
du Nord Pas-de-Calais’-CEEA 342012) and follows inter-
nationally recognized guidelines.
Stereotaxic injections and sacrifice procedures
Intracerebral injections of viral particles into the brain of
anesthetised 2-month-old Wistar rats (Ketamine 100 mg/
kg, Xylazine 10 mg/kg i.p.) were performed using classic
stereotaxic procedures at the following coordinates rela-
tive to bregma: posterior, -5.3 mm; lateral, +/- 6.2 mm;
ventral, -7 mm and -6.2 mm; depth. The injections were
performed bilaterally. The standard injection procedure
consisted of the delivery of 400 ng of p24 using a 10 μL
glass syringe with a fixed needle (Hamilton). After injec-
tion at a rate of 0.25 μl per min, the needle was left in
place for 1 min before reaching the second depth; the sec-
ond injection was performed after 5 min. Control groups
(n = nine) consisted of rats injected with PBS instead of
LVs. For anterograde tracing, 5% biotinylated dextran
amines (molecular weight 10 000 kilodaltons (kD); BDA
10 000, Invitrogen) were injected using 10 μl glass syringes
with fixed needles (Hamilton).
For immunohistochemical analyses, animals were anes-
thetised (8% chloride hydrate) at two (n = 13), four (n =
13) or eight (n = 13) months post-injection and transcar-
dially perfused first with cold 0.9% NaCl followed by 4%
PFA for 20 min before beheading. The brains were im-
mediately removed, fixed overnight in 4% PFA, placed in
20% sucrose for one week and frozen until further use.
Free-floating coronal cryostat sections (40 μm thickness)
were used for immunohistochemical analysis.
For RNA extraction, rats (n = eight) were deeply anes-
thetised using 8% chloride hydrate. Brains were dis-
sected, and 1-mm-thick coronal sections were generated
using an acrylic rat brain matrix (Electron Microscopy
Sciences). The sections were immediately frozen on dry
ice and stored at -80°C until further use.
For anterograde transport studies, rats were sacrificed 1
week post-dextran-injection and transcardially perfused
with 0.9% NaCl and 4% PFA in 0.1 mol/L phosphate-
buffered saline (pH 7.4). Brains were post-fixed for 24
hours in 4% PFA and cryoprotected before freezing for
storage. Coronal sections (40 μm thickness) were washed
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100 and incubated with fluorescein streptavidin (Vector)
for 1 hour. After three washes, sections were mounted
onto gelatine-coated slides and coverslipped with Vecta-
shield Mounting Medium (Vector).
Immunohistochemistry
The sections from the entire brain were washed in PBS-
0.2% Triton and treated for 30 min with H2O2 (0.3%).
Non-specific binding was then blocked using goat serum
(1:100 in PBS, Vector) for 60 min. Incubation with the pri-
mary antibody in PBS-0.2% Triton was performed over-
night at 4°C. After several washes, labelling was amplified
by incubation with an anti-mouse biotinylated IgG (1:400
in PBS-0.2% Triton, Vector) for 60 min followed by the
application of the ABC kit (1:400 in PBS, Vector) prior to
visualisation with 0.5 mg/ml DAB (Vector) in Tris-HCl
50 mmol/L, pH 7.6, containing 0.075% H2O2. Brain sec-
tions were mounted onto gelatine-coated slides, stained
for 1 min in a cresyl violet solution (0.5%), washed in
water with 2% acetic acid, dehydrated by passage through
a graded series of alcohol and toluene and mounted with
Vectamount (Vector) for microscopic analysis.
Immunofluorescence
For brain sections: sections from the entire brain were
washed in PBS-0.2% Triton and blocked with goat serum
(1:100 in PBS, Vector) for 60 min. Incubation with a pri-
mary antibody in PBS-0.2% Triton was performed over-
night at 4°C. After several washes, the primary antibody
against the second antigen was added in PBS-0.2% Triton,
and the sections were again incubated at 4°C overnight.
Incubation with the two Alexa Fluor secondary antibodies
(1:1000 in PBS) was performed for 60 min at room
temperature. The slides were mounted with Vectashield
containing 4′,6-diamidino-2-phenylindole (DAPI) to label
the nuclei (Vector). For cell cultures: sections were rinsed
once in 50 mmol/L NH4Cl, and cells were permeabilised
with Triton X-100 (0.1%, 10 min at room temperature).
Subsequently, the slides were incubated with primary anti-
bodies at 4°C overnight, and labelling was performed by a
reaction with the appropriate Alexa Fluor secondary anti-
bodies (1:400-Invitrogen) for 45 min at room temperature.
The cells were mounted with Vectashield medium con-
taining DAPI (Vector, Burlingame, USA).
Fluorescence imaging
Confocal microscopy was performed using a Zeiss LSM
710 inverted confocal microscope. For each optical sec-
tion, two fluorescence images were obtained. The signal
was subjected to line averaging to integrate the signal col-
lected over two or four lines to reduce noise. The confocal
pinhole was adjusted to facilitate a minimum field depth.A focal series was collected for each specimen. The focal
step between sections was typically 1 μm.
RNA extraction from brain sections and RT-PCR/PCR
RT-PCR of lentiviral mRNA was performed using total
RNA. The brain slices were lysed, and total RNA was ex-
tracted using the RNeasy Lipid Tissue kit (Qiagen, France)
according to the manufacturer’s instructions. The RNA
(1 μg) was denatured for 10 min at 68°C, and cDNA was
generated using reverse transcription with 200 nmol/L
of dNTPs, 1 ng/μl of random primers, 1 ng/μl of oligo
dT, 5 mmol/L of dithiothreitol (DTT), 2 units/μl of
RNase Out and 10 units/μl of M-MLV reverse tran-
scriptase. The viral cDNAs were then amplified using
oligonucleotides specific to human Tau (forward: 5′-
TGG-GGG-ACA-GGA-AAG-A-3′ and reverse: 5′-CCT-
CAG-ATC-CGT-CCT-CAG-TG-3′). The following pair of
primers was used to amplify murine Tau for calibration: for-
ward: 5′-CAC-AAT-GGA-AGA-CCA-GGC-C-3′ and re-
verse: 5′-TAA-GCC-ATG-GCT-CAT-GTC-TCC-3′. PCR
was performed using 2 μl of the previously obtained RT
products, reverse and forward primers (0.5 μmol/L), dNTPs
(1 μmol/L) and 0.02 unit/μl of DNA polymerase in a com-
mercial reaction buffer (GoTaq Green Master Mix, Pro-
mega). The PCR products were electrophoresed on an 8%
acrylamide gel stained with 1 μg/ml ethidium bromide.
Results
A mechanism of trans-synaptic transfer of WT Tau protein
can be demonstrated in vitro
We first determined whether the human WT Tau protein
could be transferred between neuronal cells. Using a
microfluidic device [27-29] comprising two compartments
connected through embedded microgrooves, we studied
the potential transfer of WT Tau from the somatoden-
dritic compartment seeded with rat primary neurons to
an axonal compartment seeded with a second rat pri-
mary embryonic neuronal culture. Microfluidic devices
have already been validated for the axonal transport of
recombinant α-synuclein or Tau [29,30]. To address
this question in our LVs assay and to characterise the
human Tau protein, we designed a new LV encoding a
WT Tau with a V5 epitope (See Additional file 1). First
of all, we performed several assays to control that LVs
are not able to diffuse in the microgroove or to traffic
along the microtubule (See Additional file 2).
After differentiation of rat brain primary neuronal cul-
tures [27], the hydrostatic pressure difference was re-
versed to avoid viral vector diffusion, and an LV was
added to the somatodendritic compartment to facilitate
the expression of the WT V5-Tau in rat primary neu-
rons. Simultaneously, a second rat primary embryonic
neuronal culture was seeded in the axonal compartment.
After 48 hours, V5-immunoreactivity was primarily
Figure 1 Neuron-to-cell spread of WT Tau in a microfluidic device. The microfluidic device used in our study comprised two compartments
separated by a physical barrier containing microgrooves that facilitate the passage of axons, but not neuronal cell bodies, during neuronal
differentiation. (a) Primary culture of embryonic rat cortical neurons seeded in the first compartment (somatodendritic) was infected at DIV 7 with
LVs encoding V5-hTau46WT. The flow was then reversed and a second rat primary embryonic neuronal culture cells was seeded in the axonal
compartment. (b) Forty-eight hours post-infection, the cells were processed for immunofluorescence analysis using anti-V5 antibodies and an
Alexa Fluor 488-labeled secondary antibody (green). The nuclei were counterstained with DAPI (blue). The scale bar is indicated on the figure.
These data showed that V5 is found in axons in primary neurons and in cell bodies of secondary neurons in the axonal compartment.
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axons located in the microgrooves. Interestingly, V5 im-
munoreactivity was also detected in secondary neurons,
indicating the cell-to-cell transfer of WT V5-Tau protein
via axonal transport from the primary neurons (Figure 1).
This transfer was specific to Tau since GFP was not
found in secondary neurons (See Additional file 2). Fi-
nally, all controls in the axonal compartment were nega-
tive. It is not surprising since, due to the speed of HIV
axonal transport and its time of uncoating, LVs are not
able to reach the axonal endings in the present micro-
fluidic devices where the length of microgrooves is
450 μm [31,32]. These results demonstrate in vitro that
donor neurons overexpress human WT V5-Tau, which
is transported along axons, secreted and taken up by ac-
ceptor cells.A mechanism of trans-synaptic transfer of WT Tau protein
can be demonstrated in vivo
The first aim of this study was to identify the IS in the rat
brain that would facilitate not only the monitoring of cell-
to-cell transfer of Tau protein in distant brain areas but
also to discriminate between free protein diffusion and ac-
tive transfer through anatomically organised neuronal
pathways. Using published data on the rat brain neuroanat-
omy [33], we selected stereotactic coordinates in the caudal
region of the CA1 layer, which is associated with brain re-
gions remote from the injected area and is anatomically
connected through well-defined neural networks. First, we
assessed these regions using an anterograde tracer [34], and
as expected, these areas were identified among projecting
fibres throughout the brain, i.e., those in rostral areas, such
as limbic regions, olfactory/orbital systems and caudal
Figure 2 The transfer of V5-hTau46WT protein is correlated to brain area connected to the IS (caudal part of the CA1 layer). (a) Dextran
amines (10 kD) are anterograde tracers: they were injected into the rat brain (n = 3), and one week later, the animals were sacrificed and their
brains were processed to reveal fluorescent axons efferent from the IS. Brains were virtually divided into five sections: bregma +5.20 to +1.40,
bregma +1.20 to -1.40, bregma -1.80 to -4.30, bregma -4.52 to -6.04 and bregma -6.30 to -7.80. (b) LVs encoding V5-hTau46WT were bilaterally
injected into the CA1 layer (IS; bregma -5.3) of rat brains (n = 3). Five months later, the animals were sacrificed, and the whole brain was
processed for immunohistochemical analysis using a rabbit polyclonal anti-V5 antibody. The brains were virtually divided into five sections as in
(a). The bar scale is indicated on the figure. The drawing showing the extension of WT V5-Tau protein transfer from the IS to extreme rostral and
caudal positions is illustrated in the lower part of the figure. These data showed that V5-hTau46WT Tau is transported throughout the brain using
neural networks. (c) The V5-immunoreactivity is summarized in a cartoon drawing of several coronal sections at different bregma coordinates.
The different blue intensities (level 1 to 3) indicate the density of fibres and the red stars indicate the presence of V5-immunopositive cellular
bodies indicating a trans-cellular transfer of V5-hTau46WT Tau.
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(Figure 2a). Using the LV encoding WT V5-Tau protein, we
injected rats in the CA1 region of the hippocampus. Five
months post-injection, V5-immunohistochemistry was per-
formed and V5-immunoreactivity was found in different re-
gions of the whole brain (Figure 2b). More importantly,both axonal tracer labelling and V5-were found associated
with the same regional pattern supporting that WT Tau
protein is transferred in each area connected to the IS (see
Figure 2a and b). Most of the V5-immunoreactive cell bod-
ies were observed in several connected regions in caudal
but also in rostral brain areas (Figure 2c). For instance,
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the granular layer of the olfactive bulb (GrO, Bregma +5.2).
Altogether, these analyses strongly suggest that the spatio-
temporal transfer of WT Tau is progressing through neural
networks.
A follow-up study of V5-immunoreactivity in the rat
brain was also performed at 1, 3 and 5 months post-
injection to assess the time-dependent distribution of the
tagged WT human Tau protein. As an example, we fo-
cused on two of the most rostral distant systems: the ol-
factory and the limbic areas. At 1 month post-injection,
V5-immunoreactivity was observed at the IS and in fibres
projecting in both areas. No labelled neuronal cell bodies
were observed at this stage. At 3 months post-injection, in
addition to fibres, some V5-immunoreactive cell bodies
(50 < cell bodies < 100, N = 3 rats, bregma +5.2) were visu-
alized in the olfactory area, whereas more fibres, but no
cell bodies, were observed in the limbic cortex. At five
months post-injection, numerous V5-immunoreactive cell
bodies were observed mainly in the olfactory area (cell
bodies > 100, N = 3 rats, bregma +5.2) but also in the lim-
bic regions (5 < cell bodies < 10, N = 3 rats, bregma +5.2)
(Figure 3). Such dynamic process over time supports that
WT Tau is transported through axons and then trans-
synaptically transferred to secondary neurons in differentFigure 3 In vivo trans-synaptic transfer of WT Tau protein. LVs encodin
of rat brains (n = 3 rats per group). One, three and five months later, the a
immunohistochemical analysis using an antibody to total V5-Tau. Sections
(bregma +5.2) and the CA1 (bregma -5.3, IS) are shown. The scale bars are
transported from primary to secondary neurons in a time-dependent manbrain regions. To further demonstrate that this WT Tau
transport results from an intrinsic property of the Tau spe-
cies and not from our model used to induce local overex-
pression of the transgene i.e. the LVs, different controls
were used. Indeed, one explanation for the occurrence of
Tau proteins far from the IS could be the diffusion of LVs
during the injection process, although this is unlikely to be
the case since 1) LVs delivery remains spatially restricted
to the injected area when a reporter green fluorescent pro-
tein (GFP) is used instead of WT V5-Tau protein. Indeed,
GFP protein was observed only in neurites, never in sec-
ondary neurons in connected areas (ie: the prelimbic
structures and olfactory bulb) (Figure 4a) and 2) human
Tau RNA was never detected in areas distant from the IS
(Figure 4b). Polymerase chain reaction was used to detect
human Tau RNA in sections covering the entire brain.
The presence of the human Tau RNA was restricted to
the area around the IS, where it followed a Gaussian distri-
bution for both forms of Tau. It was neither detected in
PBS-injected rats nor in areas distant from the IS in LVs-
injected animals, whereas V5 immunoreactivity in WT
V5-LVs-injected rats was found in cell bodies in connected
secondary regions (Figure 2b), supporting that the mech-
anism of cell-to-cell protein transfer is likely specific to
WT Tau protein.g V5-hTau46WT were bilaterally injected into the CA1 layer (IS; bregma -5.3)
nimals were sacrificed, and the whole brains were processed for
from the prelimbic or orbital cortex (bregma +4.7), the olfactory bulb
indicated on the figure. These data showed that V5-hTau46WT is
ner.
Figure 4 Cell-to-cell protein transfer is specific to Tau protein WT. (a) eGFP is not transported in secondary connected neurons. LVs
encoding eGFP were bilaterally injected into the CA1 layer of rat brains (IS bregma -5.3, n = 3). Eight months later, the animals were sacrificed,
and brains sections processed for immunofluorescence assays to detect eGFP. Sections from the prelimbic (bregma +4.7), external capsule
(bregma -1.8), CA1 (IS, bregma -5.3) and ectorhinal cortex (bregma -7.8) are shown. The scale bars are indicated on the figure. (b) Restricted
lentiviral insertion in the vicinity of the IS. PBS (left panel, n = 3) or LVs encoding hTau46WT (middle panel, n = 3) or hTau46P301L (right panel, n = 3)
were bilaterally injected into the CA1 layer of rat brains. One month later, the brains were dissected, and coronal sections of 1 mm thickness
(indicated as the position relative to bregma) were prepared using an acrylic rat brain matrix. Total RNA was extracted from these sections to
generate cDNA using RT-PCR. cDNAs were amplified using oligonucleotides specific to human Tau (hTau, 117 base pairs) or murine Tau (70 base
pairs). The positive control was prepared by amplifying the plasmid containing hTau sequence. The lower parts represent the mean +/-SEM of
the relative density (hTau/mTau) coming from the three rats. These data showed that Tau transport is a specific mechanism since neither eGFP
nor viral genome is found associated to distant secondary brain areas.
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expressed in CA1 neurons, can be 1) transported
through normal CA1-efferent projections even to distant
brain regions, such as the olfactory and limbic systems
and 2) secreted and transferred intercellularly to second-
ary neurons located in CA1 efferent regions.
To confirm that the V5 tag does not affect the behaviour
of Tau proteins in the trans-synaptic transfer, we compared
the observed effects to that of non-tagged Tau proteins.
The progression of Tau pathology was followed using anti-
Tau antibodies specific for different pathological states ofthe Tau protein: a hyperphosphorylated state (AT8 [35]), a
conformational change (MC1 [36,37]) and an aggregated
form (AT100 [38]) already validated in this model [22].
Antibody mappings of the whole rat brain showed differen-
tial gradients of Tau pathology spreading (Figure 5). These
data also supports that the V5 tag does not interfere with
the progression Tau pathology throughout the brain (com-
pared Figure 5a and b). More interestingly, in a two points
kinetic study, we observed that two months post-injection,
Tau pathology related to WT Tau was only weakly de-
tected at the IS, as described by Caillierez et al. [22]
Figure 5 Differential Tau spreading between WT and mutated Tau species. LVs encoding hTau46WT (n = 5, sacrificed at 2 months; n = 5,
sacrificed at 8 months) (a), V5-hTau46WT (n = 3, sacrificed at 8 months) (b) or hTau46P301L (n = 5, sacrificed at 8 months) (c) were bilaterally
injected into the CA1 layer of rat brains. After sacrifice, the whole brain was processed for immunohistochemical analysis using AT8, MC1 or
AT100 phosphorylated Tau antibodies. Among the positive rats, the rostralmost and caudalmost brain coordinates (from bregma) labeled by each
antibody were determined for each brain. The figures represent the mean values +/-SEM of the rostralmost of caudalmot brain coordinates. These
data showed that whereas hTau46P301L diffusion is restricted to the vicinity of the IS, hTau46WT has spread throughout the brain. Numbers of
immunopositive rats per group are indicated on the right of each mapping.
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observed throughout the brain 8 months post-injection
(Figure 5a).
To determine the influence of Tau species in the propa-
gation process, we then compared Tau pathology induced
by non-tagged Tau proteins with or without a P301L muta-
tion (Figure 5c). P301L exhibited a severe Tau pathology
(primarily immunoreactive for all antibodies) with a narrow
diffusion (up to 2 mm from the IS on both the rostral and
caudal sides). Conversely, WT Tau showed Tau pathology
with a wider spatial propagation in both the rostral (10
mm ahead of the IS with AT8-immunoreactivity; 4 mmahead with MC1-immunoreactivity) and caudal (greater
than 2 mm from the IS) CA1-projecting regions (Figure 5a,
Additional files 3 and 4). The pathological spreading
clearly progressed through the brain neural networks, as
evidenced by the co-localisation between phosphorylated
Tau (pTau) and anterograde tracer as well as the lack of
pTau in dextran-negative regions (Figure 2a and 6).
Transferred Tau species are mainly in a
dephosphorylated state
It remains unknown whether the AT8-immunoreactivity
observed in distant brain areas is associated with
Figure 6 Spatiotemporal progression of the Tau pathology through neural networks. LVs encoding hTau46WT were bilaterally injected
into the CA1 layer of rat brains (n = 5). Eight months later, the animals were sacrificed, and the whole brain was processed for
immunohistochemical analysis to show AT8-related pTau. The brains were virtually separated into five sections: (a) bregma +5.20 to +1.40, (b)
bregma +1.20 to -1.40, (c) bregma -1.80 to -4.30, (d) bregma -4.52 to -6.04 and (e) bregma -6.30 to -7.80. The bar scale is indicated on the figure.
These data showed that phospho-hTau46WT is found all over the brain eight months post-LVs delivery.
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question, we performed additional co-labeling assays
using WT V5-Tau five months post-injection. In distant
brain regions, the majority of the V5-immunoreactive
neurons was not AT8-immunoreactive (Figure 7a and b)
suggesting that serine residues 202 and 205 are dephos-
phorylated. We also tested the phosphorylation state of
tyrosine 18 using additional antibody, ADx215, which
recognized Tau only when this residue is dephosphory-
lated (ADx215 [4]). The immunoreactivities of both
ADx215 (Figure 7c) and V5 (Figure 7d) look like similar;
suggesting that most Tau associated to secondaryneurons in the GrO is dephosphorylated on tyrosine 18.
More interestingly, a few secondary neurons displayed
both AT8 and V5 immunoreactivities (7%), indicating
the hyperphosphorylation of the transferred human V5-
Tau protein (Figure 7e and f). It should be noted that
less than 1% of the secondary neurons in the olfactory
system were AT8-immunoreactive without any V5 label-
ling suggesting a prion-like conversion process.
Altogether, these data suggest that only a few patho-
logical Tau species are present in secondary neurons
consistent with the slow kinetics of Tau spreading in
sporadic Tauopathies.
Figure 7 Transferred Tau species are mainly in a
dephosphorylated state. LVs encoding V5-hTau46WT were bilaterally
injected into the CA1 layer (IS; bregma -5.3) of rat brains (n = 3). Five
months later, the animals were sacrificed, and the rostral areas of the
brain were processed for immunofluorescence analysis using a rabbit
polyclonal anti-V5 antibody to detect total Tau and a mouse monoclo-
nal antibody to pTau (AT8). The V5-Tau proteins were visualised in
green using the corresponding secondary antibody Alexa Fluor-488 la-
belled goat anti-rabbit IgG (a and e) and the phospho-Tau in red using
Alexa Fluor-568 labelled goat anti-mouse IgG (b and f). The scale bars
are indicated on the figure. Adjacent brain slides from the rostral areas
were assessed by immunohistochemistry using an antibody directed
against the N-terminal portion of Tau containing a dephosphorylated
tyrosine 18 residue (ADx215) (c) or an antibody to total V5-Tau (d).
Most of hTau46WT Tau species found in secondary neurons are
dephosphorylated.
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In the present study, we demonstrated in vivo that WT
Tau proteins are transferred through primary neurons
from the IS to secondary neurons in distant rat brain
areas to initiate Tau pathology. Recent studies have
shown that the Tau pathology might spread in vivo
through mono-synaptic connections in the hippocampal
formation [20,21]. Nevertheless, the transfer of Tau pro-
teins from neuron to neuron has not been conclusively
demonstrated. For example, hippocampal NFD might re-
sult from either trans-synaptic transfer or signaltransduction associated with neuronal processes, such as
receptor activation through Tau aggregation/oligomer-
isation [39,40].
In vitro, there is now considerable evidence demonstrat-
ing that Tau is secreted into the extracellular medium
[15,17,18,30,41-44] and that Tau aggregates are interna-
lised in different cell lines [15-19,41,45,46]. Nevertheless,
to date there has been no evidence of trans-synaptic pro-
tein transfer.
In vivo, Tau aggregates from P301S transgenic mice
and human brains, injected into Alz17 mice (mouse
strain overexpressing the longest Tau isoform), were
captured/internalised by neurons at the IS. Some degree
of diffusion was observed at the vicinity of the IS, remin-
iscent of Tau spreading [11,12]. In contrast, an inducible
mouse line, in which the tTA activator is driven through
a neuropsin promoter specific for the entorhinal cortex,
was cross-bred with the tetracycline-inducible Tau Tg
mouse line, rTg4510, expressing human four-repeat Tau
with the P301L mutation. In the resulting rTgTauEC
mice, neurons expressing P301L Tau species in the
trans-entorhinal cortex underwent NFD [20,21]. Associ-
ated hippocampal neurons also degenerated with time,
although there was no demonstration of a trans-synaptic
transfer, as hippocampal NFD might also result from sig-
nal transduction related to receptors activation through
Tau aggregation/oligomerisation. Moreover, the authors
reported that hippocampal neurons also express mutated
Tau species that may result from the non-specific activ-
ity of the neuropsin promoter [21,47]. To conclude, until
now, only in vivo models of Tau capture [12,48] and/or
Tau secretion have been developed [21].
The present study represents the first clear demonstra-
tion of the in vivo transfer of Tau proteins between ana-
tomically connected neurons at distant brain (d >
10 mm). Within five months, Tau proteins spread to
connected areas, such as the limbic and olfactory re-
gions, where it appeared within secondary neurons.
These V5-immunoreactive Tau species were primarily
dephosphorylated (AT8 negative, ADx215 positive), sug-
gesting that normal soluble Tau might be secreted and
transferred into secondary neurons. Altogether these ob-
servations were further supported through studies in
microfluidic chambers, where WT V5-Tau was identi-
fied, after 48 hours, in the axonal compartment in pri-
mary neurons. These results support previous data
showing that Tau is secreted in a dephosphorylated state
[41,43,49] and may activate muscarinic receptors (M1
and M3) leading to intracellular dysfunctions [40,49].
In this present study, we also demonstrated differential
Tau spreading between WT Tau and mutant P301L Tau.
Most studies of Tau propagation have used mutant
forms, although a majority of tauopathies are sporadic
and involve only the WT species and whether WT
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tant is unknown. In the present model, Tau pathology
associated with WT Tau was observed in brain areas
connected to the IS, further supporting a trans-synaptic
mechanism. In contrast, the Tau pathology induced
through mutant P301L Tau protein remained near the
LV injection site. Because P301L Tau mutant shows bet-
ter nucleation and more rapid fibrillogenesis than does
WT Tau [4], it is likely that the mutant protein might
aggregate more readily, as observed using AT100-
immunoreactivity, leaving fewer soluble species to mi-
grate through axons. Moreover, consistent with the re-
sults of Caillierez et al. [22], neuronal death is higher
with the P301L Tau mutant than with the WT Tau spe-
cies. Such differential behaviour between the two Tau
species also supports the in vivo specific trans-synaptic
transfer of soluble Tau species rather than aggregates, as
suggested using WT V5-Tau.
These findings also support the concept that Tau
transmission occurs in sporadic diseases, such as AD,
whereas Tau toxicity, leading to neuronal loss, more
readily occurs in aggressive Tauopathies (FTDP-17)
where all neurons have the mutant Tau, causing damage
without spreading [5]. Taken together, the data derived
from this in vivo model suggest that soluble/oligomeric
forms of Tau protein drive spreading as suggested by
Kayed’s group [14,50].
Finally, from data obtained from our in vivo model,
one may argue that only a few secondary neurons dis-
played AT8-immunoreactivity and that it remains un-
clear whether this effect reflects the transfer of
hyperphosphorylated Tau or a subsequent V5-Tau
hyperphosphorylation occurring in secondary neurons.
In any way, a few pathological Tau species are present in
secondary neurons. Such observations are consistent
with the slow kinetics of Tau spreading observed in
sporadic Tauopathies. For in instance, in AD, the hier-
archical spreading of Tau pathology, defined by the
Braak stages, may last for 20 years [6]. Moreover, results
generated from our model are of great relevance for fu-
ture clinical investigations. Indeed, the discovery of dis-
tinct secreted/non secreted Tau species will define new
perspectives in diagnosis of neurodegenerative diseases.
Selection of patients at the beginning of the NFD
spreading will then allowed the test of new therapeutics
that would block this spreading and subsequently slow
down the development of sporadic disease such as AD
at the asymptomatic stages of disease. In this context for
instance, Tau immunotherapy may be relevant for inter-
fering with NFD in AD and related disorders referred to
as Tauopathies. We showed previously than active im-
munotherapy allows for Tau clearance in the periphery
and improves cognitive deficits promoted by Tau path-
ology in a well-defined mutant Tau mutant model [51].More recently, passive immunotherapy further supports
the targeting of extracellular Tau [52].
Conclusions
In conclusion, independent of the mechanisms involved
in Tau spreading, we demonstrated for the first time
in vivo that the specific trans-synaptic transfer of Tau
protein from degenerating neurons might lead to the
preliminary steps of Tau pathology in secondary neu-
rons. These data are of great interest considering that
most tauopathies reflect the aggregation of Tau devoid
of mutation. In the future, this model will facilitate a
better understanding of Tau spread throughout the brain
in sporadic tauopathies.
Additional files
Additional file 1: In-vitro functionality of V5-hTau46WT. (a) Schematic
representation of the full-length 4R Tau isoform (2+3-10+) tagged with
V5 epitope (GKPIPNPLLGLDST). HEK293 cells were infected with LVs
encoding either V5-hTau46WT or hTau46WT and processed 48 hours later
for immunofluorescence analysis using a rabbit polyclonal antibody to
total V5-Tau (IF) (b), a polyclonal rabbit antibody to Tau C-Ter [23], which
recognises the carboxyl terminal region of Tau, or a polyclonal rabbit
antibody to GAPDH for biochemical assays (c) to demonstrate that the V5
tag did not alter transgene expression nor the electrophoretic mobility.
Tau proteins were visualised using the corresponding secondary
antibodies: Alexa Fluor-488 labelled goat anti-rabbit IgG antibody
(green) for IF and peroxidase goat anti-Rabbit IgG antibody for
biochemical assays. In (b), nuclei were labelled with DAPI are appear in
blue. The scale bars are indicated on the figure. In (c), NI is related to
the control non-infected cells.
Additional file 2: LVs particles are not diffusing in the
microgrooves or trafficking along the microtubules. (a) LVs were
added to the somatodendritic compartment of a microfluidic device in
the absence of cells. The flow was reversed to isolate compartments and
then prevent viral diffusion. Viral RNA was extracted from somatodendritic
and axonal compartments 5 min, 1, 12, 24 and 48 hours post-lentiviral delivery.
cDNAs were generated and amplified using oligonucleotides specific to viral
WPRE (540 bp). In the positive control, PCR was done from purified LVs
batches and in the negative one without cDNA. (b) Coomassie Blue (2%) was
added to the somatodendritic compartment in the absence of cells. The flow
was reversed (upper panels) or not (lower panels) and the presence of
colorant analysed 5 min, 1, 12, 24 and 48 later. The medium was recovered
from both compartments and the optical density (O.D. 595 nm) analysed to
determine the Coomassie Blue concentration. (c) Primary culture of embryonic
rat cortical neurons seeded in the somatodendritic compartment was infected
at DIV 7 with eGFP-LVs. The flow was then reversed and a second primary
culture of embryonic rat cortical neurons was seeded in the axonal
compartment. Forty-eight hours post-infection, cells were processed for visual-
izing eGFP fluorescence (green). The nuclei were counterstained with DAPI
(blue). The scale bar is indicated on the figure. These data showed that LVs are
not able to diffuse in the microgrooves compartment. It also showed that they
are not trafficking along the microtubule. Tau transport in the microfluidic
device is a specific mechanism since eGFP was not found associated to
secondary connected neurons.
Additional file 3: Mutant-Tau-associated Tau pathology
progression. LVs encoding hTau46P301L were bilaterally injected into the
CA1 layer of rat brains (n = 5). Eight months later, the animals were
sacrificed, and the whole brain was processed for immunohistochemical
analysis using the AT8 antibody. In the middle upper panel, the total area
positive for AT8 is represented from bregma -3.30 to bregma -7.47. The
brain was virtually separated into three parts: bregma -2.30 to -4.30,
bregma -4.52 to -6.04 and bregma -6.30 to -7.64. In each part, certain
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left), and their location in the brain is shown on the right. The
distribution of AT8 labelling (cell bodies (C) vs. neurites (N)) is
presented in the tables. The scale bars are indicated on the figure.
PhosphoTau (AT8 imunoreactivity) related to mutant Tau is restricted
to the vicinity of the IS.
Additional file 4: WT Tau-associated Tau pathology progression.
LVs encoding hTau46WT were bilaterally injected into the CA1 layer of
rat brains (n = 5). Eight months later, the animals were sacrificed, and
the whole brain is processed for immunohistochemical analyses using
AT8. In the middle upper panel, the total AT8 immunopositive area is
represented from bregma +5.20 to bregma -7.60. The brain was
virtually separated into six parts: bregma +5.20 to +2.70, +2.20 to +1.40,
bregma +1.20 to -1.40, bregma -1.80 to -4.30, bregma -4.52 to -6.04 and
bregma -6.30 to -7.80. For each part, certain regions were selected to
illustrate the Tau pathology (part left of the brain), and the total brain overlay
is shown in the right part of the brain. The distribution of AT8 labelling
(cellular bodies (C) vs. neurites (N)) is presented in the table. The scale
bars are indicated on the figure. PhosphoTau (AT8 imunoreactivity)
related to WT Tau is found all over the rat brain even in distant areas.
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